PaxMedica, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 7
- Market Cap
- $1.7M
- Website
- http://www.paxmedica.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)A Retrospective Analysis of Suramin Treatment for Stage 1 TBR
Completed
- Conditions
- Trypanosoma Brucei Rhodesiense; Infection
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Paxmedica
- Target Recruit Count
- 345
- Registration Number
- NCT06060600
- Locations
- 🇺🇸
PaxMedica, Tarrytown, New York, United States
Double Blind Trial in Children With Autism Spectrum Disorder
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Paxmedica
- Target Recruit Count
- 52
- Registration Number
- NCT06058962
- Locations
- 🇺🇸
PaxMedica, Tarrytown, New York, United States
News
No news found